KH 801
Alternative Names: KH-801Latest Information Update: 24 Jun 2024
At a glance
- Originator Beijing Kanghong Biopharmaceutical
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD24 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 May 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in China (IV) (CTR20241175)
- 17 Apr 2024 Chengdu Kanghong Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China in May 2024 (IV, Infusion)(NCT06364501)
- 05 Mar 2024 State Drug Administration approves clinical trial application for KH 801 for Solid tumours in China